MEDIAN Technologies to propose nomination of Dr. Kapil Dhingra to its Board of Directors
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Oct 26, 2012--Regulatory News: MEDIAN Technologies (Paris:ALMDT) (ALMDT), a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, announced today that the Board of Directors, chaired by Fredrik Brag, CEO, has proposed to appoint Mr. Kapil Dhingra as a new director for a period of 3 years. This decision was made at the Board’s meeting on October 4 and will be put on the agenda of the next shareholders’ meeting.
“Kapil Dhingra will bring us his unique strategic expertise, vision and experience of the global biopharma industry, ” said Fredrik Brag, CEO of MEDIAN and Chairman. “Kapil has a vast experience in bringing innovations to the drug development process in oncology. His knowledge and support will contribute to further enhance MEDIAN growth strategy, in particular as regards to the advanced imaging services that we bring to top tiers Pharmas and Biotechs. We are very proud to have him joining our Board,” Fredrik Brag added.
“Accurate and consistent evaluation of tumors is crucial to the management of patients with cancer and in clinical trials of new drugs and represents a major unmet technology need in oncology today,” said Kapil Dhingra .“The solutions provided by the MEDIAN platform can greatly enhance interpretation and management of images.The ability to obtain high quality and accurate lesion assessment in near-real-time can significantly enhance the efficiency of clinical trials of new drugs.” Dr. Dhingra founded KAPital Consulting LLC in 2008 to help biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of advances in oncology. From 1999 to 2008, he served in positions of increasing responsibility at Roche including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the Oncology Clinical Development Group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center where he led a successful laboratory as well as clinical research program.
Throughout his industry career, Dr Dhingra held an active faculty appointment at Indiana University School of Medicine from 1997 to 1999, and more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008.
Dr Dhingra holds an M.B., B.S. (equivalent to US M.D.) degree from the All India Institute of Medical Sciences (AIIMS), and has performed postgraduate work at the AIIMS, the Lincoln Medical and Mental Health Center (New York Medical College), Bronx NY and Emory University School of Medicine, Atlanta GA. He is Board-certified in Internal Medicine and Medical Oncology.
Dr Dhingra is currently an advisor to and/or member of the Board of Directors of several biotechnology and pharmaceutical companies and organizations. He has previously served on the Boards of several successful biotech companies, including Biovex and Micromet, which were acquired by major pharmaceutical companies.
About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Quintiles, to offer integrated imaging services for clinical trials to customers worldwide.
Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a US-based subsidiary.
For more information on MEDIAN, please visit: www.mediantechnologies.comCONTACT: MEDIAN Technologies Fredrik Brag, CEO, +33 4 92 90 65 82 email@example.com or Press - ALIZE RP Caroline Carmagnol, + 33 6 64 18 99 59 // + 33 1 42 68 86 43 firstname.lastname@example.org or Christian Berg, + 33 1 42 68 86 41 email@example.com KEYWORD: EUROPE FRANCE INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL OTHER HEALTH SOURCE: MEDIAN Technologies Copyright Business Wire 2012 PUB: 10/26/2012 01:30 AM/DISC: 10/26/2012 01:30 AM http://www.businesswire.com/news/home/20121025006564/